Clovis Oncology Announces First Quarter 2021 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Clovis Oncology (CLVS) Tops Q1 EPS by 8c
May 5, 2021 8:12 AM EDTClovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $38.05 million versus the consensus estimate of $44.05 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More